The FDA Is Shutting Down Compounded GLP-1s — What Your Prescription Options Are Now
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closes June 29, 2026. If finalized, large-scale compounding of these drugs will be illegal — even in future shortages.
Here's what this means for your prescription and what to do next.
What's Actually Happening
The FDA's proposal targets 503B outsourcing facilities — the large-scale compounding operations that produced millions of doses of copycat GLP-1s during the 2022–2025 shortage. These facilities compound in bulk without patient-specific prescriptions and ship nationwide.
The regulatory basis is straightforward: the 503B Bulks List only includes drugs where there's a demonstrated clinical need for compounding beyond what's commercially available. With the GLP-1 shortage resolved, FDA-approved brand-name products now available in multiple forms (injectable and oral), and safety signals mounting (455+ adverse event reports from compounded semaglutide alone), the FDA argues the clinical need no longer exists.
What About 503A Pharmacies?
503A compounding pharmacies operate under a different legal framework. They compound individual prescriptions for specific patients under state pharmacy board oversight. The proposed 503B exclusion doesn't directly change 503A law.
However, 503A pharmacies face their own restrictions. With semaglutide and tirzepatide off the shortage list, 503A pharmacies are already prohibited from regularly compounding drugs that are "essentially a copy" of commercially available products. The legal ground is narrowing, and many 503A pharmacies are adjusting their formulations to avoid being classified as copies.
Your Options Going Forward
Option 1: Brand-Name (Highest Certainty)
- Wegovy pill: $149/mo starting dose, available at 70,000+ pharmacies
- Foundayo: $149/mo via LillyDirect, no fasting required
- Wegovy injection: $199/mo intro pricing through June 2026
- Zepbound: Available via LillyDirect and retail pharmacies
Option 2: Compounded Through 503A (Still Available, Regulatory Risk)
Several telehealth platforms work with 503A pharmacies that compound patient-specific prescriptions. This pathway remains available for now, and typically costs $130–$200/mo.
Option 3: Insurance + Brand-Name
If you have commercial insurance or Medicare, check whether brand-name GLP-1s are covered. The landscape is improving: Medicare's GLP-1 Bridge launches July 2026, and more commercial plans are adding coverage.